Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 34Gynecologic 3Genitourinary 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Glioblastoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Cyclophosphamide 2vocimagene amiretrorepvec 1veliparib 1sacituzumab govitecan 1paclitaxel-Angiopep-2 conjugate 1lenvatinib 1irinotecan sucrosofate 1iniparib 1fludarabine 1depatuxizumab mafodotin 1cabozantinib 1bintrafusp alfa protein, human 1aldesleukin 1Platinum 1Nivolumab 1NVP-BKM120 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Metformin 1Mebendazole 1Ipilimumab 1Interleukin-2 1Flucytosine 1Doxycycline 1Cisplatin 1Capecitabine 1Atorvastatin 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × sacituzumab govitecan × CNS × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡